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Coronary Artery Disease (CAD) is the most prevalent cardiovascular disease, which remains the leading cause of 
death worldwide. In Indonesia, it accounts for approximately 1.5% of the entire population. Diabetes mellitus 
(DM) is taken into consideration as one of the most potent risk factors for cardiovascular diseases. Haemoglobi-
nA1c (HbA1c) reflects a long-term glycemic control and is used as a valuable diabetes biomarker. High serum 
glucose levels, expressed as glycated hemoglobin levels in diabetics or non-diabetics, are related to varying 
degrees of systemic inflammation and promote the release of the proinflammatory cytokines. The association 
between higher glycated serum HbA1c levels and the severity of the coronary disease is well known. The 
predictive value of HbA1c for CAD severity, re-hospitalization, and the mortality of cardiovascular disease had 
been studied extensively since 2004. Numerous previous trials discovered that severity of CAD correlated with the 
elevation of HbA1c levels, suggesting it as a broad surrogate marker for CAD. Thus, HbA1c is currently considered 
as an independent risk factor for CAD. A higher level of HbA1c and the presence of factors associated with 
ongoing atherosclerosis and extensive CAD are concomitantly contributing to the higher major adverse cardiovas-
cular events (MACEs) incidence and long-term mortality.
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 Coronary Artery Disease (CAD) is still the leading cause of 
death of non-communicable diseases worldwide. CAD refers to the 
pathologic process of atherosclerosis affecting the coronary arteries. It 
remains predicted to be the leading cause of death globally within the 
next 15 years, particularly in developing countries.1 Indonesia is one of 
the developing countries with a high prevalence of CAD regarding data 
from Riskesdas (2018), conducted by the Ministry of Health Republic of 
Indonesia, with an estimation of 1.5% prevalence of the Indonesian 
population.2 
 Diabetes mellitus (DM) is taken into consideration as one of 
the major potential risk factors for cardiovascular disease. Compared to 
non-diabetes of the same sex, age, and ethnicity, the excess risk for 
cardiovascular disease was found to be two to eight times higher in 
patients with diabetes mellitus.3 Glucotoxicity and lipotoxicity leading 
to prolonged hyperglycemia and the dysfunction of beta-cell are revers-
ible early pathophysiological events. This suggests that the course of 
hyperglycemia and prevent or delay long-term complications can be 
changed by proper management.4 
 
 Hemoglobin A1c (HbA1c) indicates long-term glycemic 
control, which also tracks well in individuals over time, in comparison 
to fasting glucose specifically. In diabetics, HbA1c is associated with 
microvascular disease development and is central to hyperglycemia's 
clinical management. Even though there is evidence that HbA1c levels 
are also related to macrovascular disease in people with diabetes, this 
association remains controversial.5,6 Vascular complications can 
develop in patients with HbA1c <7.0% and even in undiagnosed 
patients because of a transient increase in plasma glucose concentra-
tion. Macrovascular complications may develop early and do not 
linearly correlate to HbA1c, as well as microvascular complications. It 
appears that chronic hyperglycemia is significant in CAD pathogenesis 
and would extend to individuals with the elevation of HbA1c levels 
even without a diabetes diagnosis.4 
 HbA1c is a valuable diabetes biomarker used worldwide. 
Mendel's randomization found genetic evidence that HbA1c is a risk 
factor for CAD representing two different etiologic pathways, glycemic 
and erythrocytic. The ability of HbA1c to predict CAD risk likely goes 
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Figure 1. Forest Plot For Long-Term Mortality.10 
Figure 2. Forest Plot For Re-infarction During Follow-Up.10
 In conclusion, many data support the involvement of HbA1c 
as an independent risk factor for CAD. A significant correlation was 
shown between HbA1c, admission to hospital, coronary artery severity, 
and adverse cardiovascular events, which could act as a surrogate for 
worse long-term outcomes. Therefore, it is recommended that HbA1c 
levels be maintained within normal limits (below 5.7%). Higher HbA1c 
levels and the presence of factors such as changes in blood glucose 
levels can be associated with ongoing atherosclerosis and extensive 
CAD, and together can lead to higher long-term mortality.
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beyond its reflection of ambient glycemia and suggests the importance 
of further research into the biology underlying the HbA1c-CAD associa-
tion.6 High serum glucose levels expressed in glycated hemoglobin 
levels in diabetic or non-diabetic individuals are related with varying 
degrees of systemic inflammation and promotes the release of the 
proinflammatory cytokines. The relation between higher glycated 
hemoglobin levels in the blood with coronary disease severity and 
hospital admission was associated with low-grade vascular inflamma-
tion and long-term promotion of atherogenesis.7
 Selvin et al. (2005) showed that the elevation of HbA1c 
levels was an independent risk factor for CAD in people with and 
without diabetes.5 Glycosylated HbA1c is an important biomarker that 
considers fasting and postprandial plasma glucose concentrations over 
the previous 2-3 months.3,8 HbA1c has been taken into consideration as 
the standard criterion for monitoring and diagnosing diabetes mellitus 
(DM) for many years. It has several advantages over oral glucose 
tolerance tests and fasting plasma glucose, including greater comfort, 
greater pre-analysis stability, and less daily distraction during stress 
and illness. HbA1c has been recommended by The American Diabetes 
Association (2019) as the most effective diagnostic and prognostic tool 
for DM and its complications.9 Selvin et al. (2005) shows that even CAD 
risk could start at HbA1c less than 7%, the usual target for good 
glycemic control. Thus, well into the "normal” range (i.e., between 
4.6% and 6.0%), HbA1c values relate to CAD. The current study 
provides guidance on the informative range of HbA1c for CAD risk and 
suggests that future studies of HbA1c and cardiovascular risk in non-di-
abetic individuals should be considered.5 Since 2004, the predictive 
value of HbA1c for the severity of CAD and cardiovascular mortality in 
non-diabetes has been extensively studied. Elevation of HbA1c levels 
was found in many trials to be related with CAD severity, indicating it 
as an extensive marker of CAD.3 
 Based on research by Timmer and Pai on non-diabetic adults, 
the Atherosclerosis Risk In Communities (ARIC) study (2015), a higher 
HbA1c level was related to higher cardiovascular disease and mortali-
ty.6,9 Ghaffari et al. (2015), which evaluate the correlation of HbA1c 
with CAD severity using the Califf scoring system in STEMI patients, 
demonstrated similar results as well. Levels of HbA1c on admission 
correlated with short-term and in-hospital outcomes of non-diabetic 
patients presenting with STEMI. This study showed HbA1c level > 
5.8% in non-diabetic patients with STEMI was related to severe CAD 
and the involvement of coronary artery multivessel as well. Although 
the same complications and mortality occurred during the hospitaliza-
tion period, the significant decrease of 1 year survival in patients with 
HbA1c level > 5.8% was observed. Among these cases, the percentage 
of cardiovascular disease-related re-hospitalization was also higher 
than the HbA1c percentage below the median value.7
 A meta-analysis conducted by Geng et al.  (2017) demon-
strated an association between elevated HbA1c level and higher 
long-term mortality (shown in Figure 1) and higher re-infarction 
incidence (shown in Figure 2). HbA1c 5.7% to 6.5% is considered 
prediabetes, according to the most recent guidelines for the diagnosis of 
diabetes mellitus. In this meta-analysis, eight studies presented the 
HbA1c threshold of 5.7%, and subgroup analysis of HbA1c levels 
showed a significant association between prediabetes and long-term 
mortality. (OR 1.31, 95% CI 1.10–1.55).10   
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